🚨Don’t miss our practical approach to address and optimize cardiorenal therapies and related comorbidities in chronic cardiorenal disease beyond congestion! This is a proposal prepared by Síndrome CardioRenal y Congestión en IC @ICyFA-SEMI S.E.N. Nefrología 💪🏻 🧵 1/9

2/9 💊 This is our HFrEF therapy proposed approach depending on eGFR

3/9 🩸 Which studies should be performed in patients with cardiorenal disease and anemia? How do we treat anemia in these patients?

4/9 Potassium binders should be prescribed in cardiorenal patients when plasmatic potassium levels are ≥5.0 mmol/L to prevent adverse events and to facilitate the implementation of optimal doses of RAASi 👇🏻

5/9 ❤️ Risk Factors! What should be the treatment of diabetes mellitus, dyslipidemia, arterial hypertension, and obesity in patients with cardiorenal disease?

6/9 Atrial Fibrillation! What options for anticoagulation do we have in advanced kidney disease? What about left atrial appendage closure?

7/9 🦴 How do we assess the mineral and bone metabolism in patients with cardiorenal disease? What are the targets and what drugs should be used?

8/9 Malnutrition and sarcopenia! How do we evaluate and treat malnutrition and sarcopenia?

9/9 Prevention of contrast-associated acute kidney injury! What is the best strategy to avoid CA-AKI in patients with cardiorenal disease?

Many thanks to all the authors!!!Specially to Marta Cobo Marcos !
And don’t forget to check our paper in karger.com/crm/article/14…